Investigators from Abzyme Therapeutics LLC have hypothesized that inhibiting this pathway in the CNS may prevent tissue damage and cease the progression of multiple sclerosis (MS).

Annexon Inc.’s stock (NASDAQ:ANNX) climbed 31% June 4 following news that a single infusion of C1q protein complex inhibitor ANX-005 at the 30-mg/kg dose delivered a statistically significant 2.4-fold improvement in Guillain-Barré syndrome patients. Shares closed at $5.99, up $1.41.

Amyotrophic lateral sclerosis (ALS) is associated with loss of synaptic connectivity at the neuromuscular junction (NMJ) and loss of motor neurons.

Investigators working at Gladstone Institutes reported new insights into sleep disturbances and seizures that can be a late consequence of even mild traumatic brain injuries (TBI), and how we may one day best treat these conditions by targeting the complement pathway.